This 2018 Texas human review subject was prostate cancer epigenetics:
“We comprehensively review the up-to-date roles of epigenetics in the development and progression of prostate cancer. We especially focus on three epigenetic mechanisms: DNA methylation, histone modifications, and noncoding RNAs. We elaborate on current models/theories that explain the necessity of these epigenetic programs in driving the malignant phenotypes of prostate cancer cells.
It is now generally accepted that epigenetics contributes to the development of nearly every stage of PCa [prostate cancer]. Considering the highly heterogeneous nature of PCa, it is quite likely that [the] effect of a particular epigenetic pattern on growth of cancer cells varies from case to case and [is] context specific.
Restoration of a “normal” epigenetic landscape holds promise as a cure for prostate cancer.”
The review’s Epigenetic Therapy section explained much of what’s going on in the above graphic. Its Table 3 was instructive for up-to-date clinical trial information on epigenetic treatments of prostate cancer.
“Restoration of a “normal” epigenetic landscape” won’t guarantee a healthy outcome once diseases start. Prevention seems desirable to avoid the situation where:
“Numerous epigenetic alterations reinforce the establishment of a context-specific transcriptional profile that favors self-renewal, survival, and invasion of PCa cells.”
http://www.ajandrology.com/preprintarticle.asp?id=238758 “Epigenetic regulation of prostate cancer: the theories and the clinical implications”